Partial seizures with or without secondary generalisation
Adult: As adjunctive therapy: Initially, 2 mg once daily at bedtime. Maintenance: 4-8 mg daily. Adjust doses in increments of 2 mg daily at intervals of at least every 2 weeks according to clinical response and tolerability. Max: 12 mg daily. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: As adjunctive therapy: 4-11 years <20 kg: Initially, 1 mg once daily at bedtime; may adjust in increments of 1 mg daily. Maintenance: 2-4 mg daily; depending upon the patient’s clinical response and tolerability at a dose of 4 mg daily, may adjust the dose in increments of 0.5 mg daily to 6 mg daily. Max: 6 mg daily; 20-<30 kg: Initially, 1 mg once daily at bedtime. Maintenance: 4-6 mg daily. May adjust doses in increments of 1 mg daily. Max: 8 mg daily; ≥30 kg: Same as adult dose. All doses are adjusted at intervals of at least every 2 weeks according to clinical response and tolerability. ≥12 years Same as adult dose. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: As adjunctive therapy: 4-11 years <20 kg: Initially, 1 mg once daily at bedtime; may adjust in increments of 1 mg daily. Maintenance: 2-4 mg daily; depending upon the patient’s clinical response and tolerability at a dose of 4 mg daily, may adjust the dose in increments of 0.5 mg daily to 6 mg daily. Max: 6 mg daily; 20-<30 kg: Initially, 1 mg once daily at bedtime. Maintenance: 4-6 mg daily. May adjust doses in increments of 1 mg daily. Max: 8 mg daily; ≥30 kg: Same as adult dose. All doses are adjusted at intervals of at least every 2 weeks according to clinical response and tolerability. ≥12 years Same as adult dose. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Oral
Primary generalised tonic-clonic seizures
Adult: In patients with idiopathic generalised epilepsy: As adjunctive therapy: Initially, 2 mg once daily at bedtime. Maintenance: Up to 8 mg daily. Adjust doses in increments of 2 mg daily at intervals of at least every 2 weeks according to clinical response and tolerability. Max: 12 mg daily.
Child: In patients with idiopathic generalised epilepsy: As adjunctive therapy: 7-11 years <20 kg: Initially, 1 mg once daily at bedtime; may adjust in increments of 1 mg daily. Maintenance: 2-4 mg daily; depending upon the patient’s clinical response and tolerability at a dose of 4 mg daily, may adjust the dose in increments of 0.5 mg daily to 6 mg daily. Max: 6 mg daily; 20-<30 kg: Initially, 1 mg once daily at bedtime. Maintenance: 4-6 mg daily. Adjust in increments of 1 mg daily. Max: 8 mg daily; ≥30 kg: Initially, 2 mg once daily at bedtime. Maintenance: 4-8 mg daily. May adjust doses in increments of 2 mg daily. Max: 12 mg daily. All doses are adjusted at intervals of at least 2 weeks according to clinical response and tolerability. ≥12 years Same as adult dose. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Child: In patients with idiopathic generalised epilepsy: As adjunctive therapy: 7-11 years <20 kg: Initially, 1 mg once daily at bedtime; may adjust in increments of 1 mg daily. Maintenance: 2-4 mg daily; depending upon the patient’s clinical response and tolerability at a dose of 4 mg daily, may adjust the dose in increments of 0.5 mg daily to 6 mg daily. Max: 6 mg daily; 20-<30 kg: Initially, 1 mg once daily at bedtime. Maintenance: 4-6 mg daily. Adjust in increments of 1 mg daily. Max: 8 mg daily; ≥30 kg: Initially, 2 mg once daily at bedtime. Maintenance: 4-8 mg daily. May adjust doses in increments of 2 mg daily. Max: 12 mg daily. All doses are adjusted at intervals of at least 2 weeks according to clinical response and tolerability. ≥12 years Same as adult dose. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).